An undiagnosed allergy could be the reason your nasal polyp treatment may not be working. “It’s important to assess for allergies, as this is the cause of inflammation and polyps in some cases ...

Consuming foods like refined sugar and alcohol may lead to inflammation, which can worsen your nasal polyps. In fact, “highly processed foods, particularly ultra-processed foods, have been ...

KEY POINTS Chronic rhinosinusitis refers to symptomatic inflammation of the nose and paranasal sinuses that has been present ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

The "Sinusitis Pipeline Insight Analysis Report" drug pipelines has been added to ResearchAndMarkets.com's offering.The sinusitis treatment pipeline analysis provides an overview of recent ...

IT breaks my heart to have read that GP teams are seeing an increase in abuse from patients. We are in the midst of a GP crisis which can leave people suffering, in pain and at times despair, ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U ...